Clinical parameters | OR (95% CI) | P |
---|---|---|
Gender (male/female) | 1.27 (1.043–1.545) | 0.017 |
Age (> 60/ ≤ 60 years) | 0.596 (0.480–0.740) | < 0.001 |
HBsAg (positive/negative) | 1.262 (1.075–1.482) | 0.004 |
HBV-DNA (≥ 103/< 103 copies/mL) | 1.529 (1.164–2.010) | 0.002 |
HBeAg (positive/negative) | 1.771 (1.170–2.681) | 0.007 |
AFP | Â | Â |
 (< 20/20–400 ng/mL) | 1.337 (1.171–1.527) | < 0.001 |
 (< 20/ > 400 ng/mL) | 1.582(1.277–1.960) | < 0.001 |
NEU (> 3.56/ ≤ 3.56 × 109/L) | 1.621 (1.241–2.117) | < 0.001 |
LYM (> 1.1/ ≤ 1.1 × 109/L) | 1.221 (0.993–1.502) | 0.059 |
PLT (> 100/ ≤ 100 × 109/L) | 1.472 (1.189–1.821) | < 0.001 |
NLR (> 3/ ≤ 3) | 2.000 (1.429–2.799) | < 0.001 |
PLR (> 111/ ≤ 111) | 1.687 (1.247–2.282) | 0.001 |
TB (> 28/ ≤ 28 μmol/L) | 2.000 (0.684–5.581) | 0.206 |
ALT (> 50/ ≤ 50 IU/L) | 1.368 (1.000–1.870) | 0.05 |
AST (> 40/ ≤ 40 IU/L) | 1.602 (1.218–2.108) | 0.001 |
ALB (> 40/ ≤ 40 g/L) | 1.184 (0.947–1.482) | 0.139 |
ALBI grade (1/2/3) | 0.781 (0.523–1.168) | 0.229 |
GGT (> 60/ ≤ 60 IU/L) | 1.697 (1.306–2.205) | < 0.001 |
PT (> 12.8/ ≤ 12.8 s) | 1.164 (0.812–1.668) | 0.41 |
INR (> 1.15/ ≤ 1.15) | 1.244 (0.841–1.842) | 0.275 |
Fib (> 2/ ≤ 2 g/L) | 1.079 (0.873–1.335) | 0.482 |
Tumor size | Â | Â |
 (≤ 5/5–10 cm) | 3.279 (2.189–4.910) | < 0.001 |
 (≤ 5/ > 10 cm) | 2.031 (1.497–2.755) | < 0.001 |
Tumor number | Â | Â |
 (1/2) | 2.295 (1.262–4.174) | 0.007 |
 (1/3) | 2.069 (1.193–3.588) | 0.010 |
BCLC stage (A/B) | 3.056 (1.795–5.203) | < 0.001 |
Cirrhosis (present/absent) | 1.193 (0.949–1.499) | 0.131 |
Differentiation (I + II/III + IV) | 1.819 (1.365–2.426) | < 0.001 |
MVI (present/absent) | 2.923 (2.133–4.005) | < 0.001 |
Satellite lesion (present/absent) | 2.429 (1.461–4.037) | 0.001 |
Resection (anatomic/non-anatomic) | 1.475 (1.146–1.899) | 0.003 |